In October 2022, it was nice to see some of the newer blog posts featuring rather than the old favourites. That guy Steve Jobs is there but only because I posted about the anniversary of his death on October 5th.
Here are the 5 most read posts in October 2022.
Evidence of disease but stable
Evidence of disease but stable. People get fixated on these terms, or not even be aware of what they actually mean…. but the aim of this blog post was to say that even with Evidence of Disease (ED) you can still be stable.
Click here or on the picture to read more:
Steve Jobs – the most famous Neuroendocrine Cancer Ambassador we NEVER had
Steve Jobs – the most famous Neuroendocrine Cancer Ambassador we NEVER had. Still a draw 11 years after his death. Every share is awareness for NET.
Click here or on the picture to read more:
Neuroendocrine Cancer: Glossary of Terms
Neuroendocrine Cancer: Glossary of Terms – a year’s worth of work, take a look, please.
Understanding your Somatostatin Receptor (SSTR) PET Results
Hopefully will help with perspective and provide a basis for asking questions to understand your report. Click here or on the picture to read more:
Living with cancer: 5 tips for facing things you can’t control
I’m wired not to worry too much about something I cannot control. For example, I automatically ignore any concerns about being inside an imaging device and then having to wait for the results to come through. For me, I need to get the scan and I cannot control the results. The results will be what they will be, and I will react accordingly when I know them. I once wrote an article called “Scanxiety, I just don’t get it“. In hindsight, perhaps I was a bit harsh as not everyone is wired like me. However, perhaps presenting the reasons for my own way of handling these test and surveillance events might help others. So based on my own experience, here are my 5 tips to face things you cannot control. Click here or on the picture to read more:
October 2022 – RonnyAllan.NET clicked over 2 million views
Click on the picture to read more
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
What is Carcinoid Syndrome? Carcinoid syndrome (CS) is the most frequent hormonal complication accompanying neuroendocrine neoplasms (NENs) and is defined by chronic diarrhoea and/or flushing in the
I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is
November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine